RSS-Feed abonnieren
PDF herunterladen
DOI: 10.5935/1806-6054.20180007
Year in Review 2018: Lung Cancer
Revisão Ano 2018: Câncer de PulmãoAutor*innen
Financial support: none to declare.
ABSTRACT
Over the past decade, significant progress has been achieved for clinical management of lung cancers, including screening strategies, use of immunotherapy-based approaches to treat locally advanced and metastatic disease, and development of novel targeted agents for molecularly defined subgroups. In this review, we summarize the studies published/presented in 2018 that form the basis for new standard-of-care management options for lung cancers. These practice-changing studies exemplify the importance of multidisciplinary, evidence-based care to improve outcomes for lung cancer patients.
RESUMO
Durante a última década, foi alcançado um progresso significativo no tratamento clínico de câncer de pulmão, incluindo estratégias de rastreamento, uso de abordagens baseadas em imunoterapia para tratar a doença localmente avançada e a metastática, e o desenvolvimento de novos agentes direcionados para subgrupos definidos molecularmente. Nesta revisão, resumimos os estudos publicados/apresentados em 2018 que formam a base para novas opções de tratamento padrão para o câncer de pulmão. Esses estudos que mudam a prática exemplificam a importância de cuidados multidisciplinares baseados em evidências para melhorar os resultados para pacientes com câncer de pulmão.
Publikationsverlauf
Eingereicht: 28. November 2018
Angenommen: 29. November 2018
Artikel online veröffentlicht:
07. März 2025
© 2022. This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
-
REFERENCES
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A.. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (06) 394-424
- De Koning H, Van Der Aalst C, Ten Haaf K, Oudkerk M. PL02.05 Effects of Volume CT Lung Cancer Screening: Mortality Results of the NELSON Randomised-Controlled Population Based Trial. J Thorac Oncol 2018; 13 (10) S185
- National Lung Screening Trial Research Team. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM. et al Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365 (05) 395-409
- Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R. et al PACIFIC Investigators. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med 2017; 377 (20) 1919-1929
- Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R. et al PACIFIC Investigators. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med 2018; Sep 25. . Epub ahead of print
- Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F. et al KEYNOTE-189 Investigators. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med 2018; 378 (22) 2078-2092
- Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüs M, Mazières J. et al KEYNOTE-407 Investigators. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med 2018; 379 (21) 2040-2051
- Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS. et al Brigatinib versus Crizotinib in ALK- Positive Non-Small-Cell Lung Cancer. N Engl J Med 2018; 379 (21) 2027-2039
- Popat S, Kim HR, Ahn MJ, Yang JC, Han JY, Hochmair MJ. et al Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial. Ann Oncol 2018; 29 (Suppl 8): mdy424.070
- Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, Hochmair MJ. et al IMpower133 Study Group. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med 2018; Sep 25. Epub ahead of print